Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epeleuton in Acute Decompensated Alcoholic Hepatitis
NCT03452540Phase 2Terminated
- Sponsor
- Afimmune
- Start
- Nov 2018
- Primary completion
- Jun 2019
- Modality
- Classical Binding Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of epeleuton in alcoholic hepatitis (AH), sponsored by Afimmune. Started Nov 2018; status: terminated.
02
Drugs
epeleuton
03
Conditions
alcoholic hepatitis (AH)
Beyond the preview
Go deeper on NCT03452540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03452540.